Authors: Dr. C. Ascehle on behalf of the STAR Network Investigators
description
Transcript of Authors: Dr. C. Ascehle on behalf of the STAR Network Investigators
![Page 1: Authors: Dr. C. Ascehle on behalf of the STAR Network Investigators](https://reader036.fdocuments.us/reader036/viewer/2022081520/56815af5550346895dc8b18a/html5/thumbnails/1.jpg)
www.OncologyEducation.ca
Preoperative fluorouracil (FU)-based chemoradiation +/- weekly oxaliplatin in locally advanced rectal cancer. Pathologic response
analysis of the STAR (Studio Terapia Adiuvante Retto)-01 randomized phase III trial
Authors: Dr. C. Ascehle on behalf of the STAR Network InvestigatorsDate posted: ASCO Oral Presentation June 2009Reviewed by Dr. Christopher Booth
![Page 2: Authors: Dr. C. Ascehle on behalf of the STAR Network Investigators](https://reader036.fdocuments.us/reader036/viewer/2022081520/56815af5550346895dc8b18a/html5/thumbnails/2.jpg)
www.OncologyEducation.ca
RTreatment A:
50.4 Gy with 5-FU CIV 225 mg/m2/d
Treatment B:
50.4 Gy with 5-FU CIV 225 mg/m2/d PLUSOxaliplatin 60 mg/m2 weekly x 6cT3/4 or cN+
resectablerectal cancer
N=747
All cases had TME 6-8 weeks later and post-op adjuvant 5-FU chemo as per centre policyPrimary EP was OS
![Page 3: Authors: Dr. C. Ascehle on behalf of the STAR Network Investigators](https://reader036.fdocuments.us/reader036/viewer/2022081520/56815af5550346895dc8b18a/html5/thumbnails/3.jpg)
www.OncologyEducation.ca
RESULTS
5-FU CRT5-FU, oxali
CRTp-value
Path CR 16% 16% 0.94
Gr 3-4 toxicityAny
Diarrhea8%4%
24%15%
<0.0001<0.0001
Grade 2-3 neurosensory 0.5% 36% <0.0001
![Page 4: Authors: Dr. C. Ascehle on behalf of the STAR Network Investigators](https://reader036.fdocuments.us/reader036/viewer/2022081520/56815af5550346895dc8b18a/html5/thumbnails/4.jpg)
www.OncologyEducation.ca
STUDY COMMENTARY
• This trial sought to improve on outcomes in rectal cancer by adding oxaliplatin to standard 5-FU based CRT
• The trial primary EP was OS which is not yet reported
• This presentation related to the secondary EP of pathologic CR and toxicity
• Surprisingly, these data do not show ANY improvement in rate of pathologic CR when oxaliplatin is added to standard 5-FU based neoadjuvant CRT
• Oxaliplatin added substantial toxicity to treatment
![Page 5: Authors: Dr. C. Ascehle on behalf of the STAR Network Investigators](https://reader036.fdocuments.us/reader036/viewer/2022081520/56815af5550346895dc8b18a/html5/thumbnails/5.jpg)
www.OncologyEducation.ca
BOTTOM LINE FOR CANADIAN MEDICAL ONCOLOGISTS
• Standard of care for stage II/III rectal cancer remains 5-FU based neoadjuvant CRT without oxaliplatin.